MERIT-HF trial
This trial assessed the effects of beta-1-blocker metoprolol on patients with heart failure. The trial design was randomised, double-blind with a mean follow-up of one year. (1)
- 3391 patients with chronic heart failure were recruited into the study; before randomisation patients also had to be receiving optimal treatment (diuretics with ACE inhibitors)
- Of the 1990 treated with metoprolol, 641 patients died or were admitted to hospital as opposed to 767 out of 2001 patients who received placebo. The total mortality or hospitalisation due to heart failure was reduced by one third in the metoprolol group
The conclusion reached was that the use of metoprolol in patients with chronic heart failure led to a reduced mortality rate and less hospital admissions.
Reference
- Fagerberg B, et al. "Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure". The Lancet. 1999. 353(9169):2001-7.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.